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Letter to the Editor 
The role of serology for COVID-19 control: Population, kinetics 
and test performance do matter 
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Accumulating evidence in the literature exemplifies the failings
f real-time polymerase chain reaction (RT-PCR) as a sole diagnos-
ic method in COVID-19 surveillance, because of its inability to de-
ect past infection. 1-4 The authors of these reports or correspon-
ence highlighted the added value of serological testing, which,
f captured within the correct timeframe after disease onset, can
etect both active and past infections. 1 By providing estimates of
ho is and is not immune to SARS-CoV-2, serological data can be
sed to estimate epidemiological variables, such as the attack rate
r case-fatality rate, which are necessary to assess how much com-
unity transmission has occurred and its burden. 5 They can also
e used to strategically deploy immune health-care workers to re-
uce exposure of the virus to susceptible individuals or to assess
he effect of non-pharmaceutical interventions at the population
evel and inform policy changes to release such measures. 6 In the
ear future, serological testing will be required to assess the effec-
iveness of vaccine candidates and finally, they are also useful to 
ig. 1. Antibody kinetics expressed as change from baseline or sensitivity at week
etermination and confirmation of SARS-CoV-2 infection. True positivity rates (sensitiv
rovided by the manufacturer. ttps://doi.org/10.1016/j.jinf.2020.05.019 
163-4453/© 2020 The British Infection Association. Published by Elsevier Ltd. All rights r2 and 3 post RT-PCR COVID-19 positivity. Week 0 corresponds to the day of RT-PCR
ve been assessed with the cut-offs adapted from our validation and with the cut-off
dentify individuals who developed a strong immunological re-
ponse to the virus and whose antibody isolates can be used to
reat patients via plasma therapy. 7 
However, several challenges still remain to correctly address
he appropriate implementation, validation and interpretation of
erological testing. Among them, understanding the kinetics of
he antibodies matters as divergent opinion are reported in the
iterature. 8 , 9 Our group recently reported the validation of a 
hemiluminescence immunoassay (CLIA) for IgG determination 
LIAISON R ©SARS-CoV-2, DiaSorin R ©, Saluggia, Italy) and reported the
xcellent analytical and clinical performance of the assay. However,
ata on antibody kinetics and assessment of IgA were not con-
eyed yet on this cohort. 
The sera from 182 symptomatic patients, positive for RT-
CR at admission, were included and assessed at different
ime points for dosing IgA (ELISA method, Euroimmun Medi-
inische Labordiagnostika R ©, Lübeck, Germany) and IgG (ELISA
ethod, Euroimmun Medizinische Labordiagnostika R © and CLIA
IAISON R ©SARS-CoV-2, DiaSorin R ©). The complete follow-up at the
 different time points was obtained for 15 of them. Statistical
nalyses show they are representative of the full cohort. eserved. 
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 Fig. 1 reports the change from the baseline and sensitivity at
weeks 0, 1, 2 and 3 for IgA and IgG determinations. Both im-
munoglobulin levels increase over time and tend to stabilize af-
ter two weeks. Using our adapted cut-off, IgA determination shows
a sensitivity of 100% after one week while it reaches 87% for IgG
testing. The cut-off provided by the manufacturer still shows a sen-
sitivity of 100% for IgA but it diminishes to 80% and 67% for IgG
ELISA and IgG CLIA, respectively. After two weeks, all tests demon-
strate a sensitivity of 100%, as reported by other groups, 8 , 10 except
when the cut-off provided by the manufacturer were used for IgG
detection (i.e. one of our 15 patients was never considered as pos-
itive). 
These observations are of upmost importance for at least two
analytical and clinical matters: first, the selection of the appropri-
ate timeframe is essential for the detection of immunity. Namely,
these results show that IgA immunity can be accurately detected
one week after the RT-PCR positivity while IgG immunity has to be
assessed after two weeks to avoid false negative results. Secondly,
adapted cut-offs have to be established by each laboratory in or-
der to improve the sensitivity of the commercial assays. However,
this implies that the sera selected to define the adapted cut-off is
crucial. In our case, the cut-off was determined on samples from
symptomatic patients collected 14 days after the positive RT-PCR.
Of note, there is to date no consensus on how to define the dis-
ease onset, i.e. date of first COVID-19 symptoms or date of RT-PCR.
Despite being both validated and approved by competent au-
thorities, these results show that the two IgG assays are not similar
for determining positivity if measurement is performed at the time
of RT-PCR determination (i.e. sensitivity of 7 and 20% for the CLIA
and the ELISA method, respectively using the manufacturer cut-
off). This further complexifies the interpretation of the results and
highlights the need for competent national authorities and learned
societies to establish guidance and procedures for serological test-
ing to avoid misinterpretation of too early determination, leading
to a high rate of false negative results. 
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